Double-blind, randomised, placebo-controlled trial of levetiracetam for central neuropathic pain in patients with multiple sclerosis

INTERVENTION: Trade Name: Keppra Product Name: Levetiracetam Product Code: ucb L059 Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use CONDITION: PRIMARY OUTCOME: Main Objective: To determine if levetiracetam will relieve central neuropathic pain in multiple sclerosis; ; ; Primary end point(s): Patients verbal score of pain relief (complete, good, moderate, slight, no, worse) at the end of each treatment period Secondary Objective: In patients with central neuropathic pain in multiple sclerosis to determine the effect of levetiracetam ; 1‐ specific pain symptoms; 2‐on quality of life; 3‐pain related sleep disturbance; 4‐on spasticity; ; ; ; INCLUSION CRITERIA: 1.The diagnoses multiple sclerosis verified by neurologist 2.age over 18 years 3.neuropathic pain which for at least 3 months and had its onset at least 6 months after the diagnoses multiple sclerosis had been verified 4.average baseline pain score of at least 4 on a 0 to 10 numeric rating scale 5.informed consent Are the trial subjects under 18? Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range